Clinical Trials
Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
Gynecologic Cancer Trials
-
STUDY17022
First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Study Information
-
STUDY17262
Combination of Autophagy Selective Therapeutics (COAST) in Relapsed Gynecological Cancers, Relapsed Prostate Cancer, or other Advanced Solid Tumors, a Phase I/II Trial
Autophagy is a cancer cell survival mechanism that is involved in cancer growth, treatment resistance, and metastasis. Hydroxychloroquine and nelfinavir mesylate are agents that inhibit the process of autophagy. Metformin, dasatinib, and sirolimus stress autophagy.
Study Information
-
STUDY21108
GOG-3076 a Phase 3 Trial in Platinum-Resistant/Refractory Ovarian Cancer
Study Information
-
STUDY21361
A Phase 1/2 Open label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
This study will assess the safety and tolerability of multiple dose levels of PC14586 in participants with advanced solid tumors containing a p53 Y220C mutation.
Study Information
-
STUDY21565
A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor (Endometrial cohort enrolling 2nd and 3rd line patients.)
To assess safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of
E7386 in combination with other anticancer drug(s). To assess pharmacokinetic (PK) profile of study drug(s)
To assess efficacy (objective response rate [ORR], best overall response [BOR], disease control
rate [DCR], clinical benefit rate [CBR], progression-free survival [PFS], overall survival [OS],
and duration of response [DOR]) of E7386 in combination with other anticancer drug(s)
(Revised per Amendment 06)
Study Information